Davenport & Company Cut By $459.34 Million Its C (C) Position; 9 Analysts Are Bullish Summit Therapeutics plc (SMMT) Last Week

Citigroup Inc. (NYSE:C) Logo

Among 10 analysts covering Summit Therapeutic (NASDAQ:SMMT), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. Summit Therapeutic had 18 analyst reports since August 19, 2015 according to SRatingsIntel. The stock of Summit Therapeutics plc (NASDAQ:SMMT) earned “Buy” rating by Canaccord Genuity on Wednesday, April 11. RBC Capital Markets maintained the stock with “Outperform” rating in Wednesday, November 16 report. The company was maintained on Thursday, June 15 by Canaccord Genuity. Oppenheimer maintained it with “Outperform” rating and $30 target in Friday, January 26 report. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, July 6 report. As per Friday, April 13, the company rating was maintained by SunTrust. Oppenheimer maintained Summit Therapeutics plc (NASDAQ:SMMT) rating on Thursday, June 22. Oppenheimer has “Buy” rating and $2400 target. The stock has “Buy” rating by H.C. Wainwright on Friday, December 1. H.C. Wainwright initiated the stock with “Buy” rating in Friday, September 16 report. Janney Capital initiated Summit Therapeutics plc (NASDAQ:SMMT) on Tuesday, June 21 with “Buy” rating. See Summit Therapeutics plc (NASDAQ:SMMT) latest ratings:

02/05/2018 Broker: Janney Capital Rating: Buy New Target: $27 Initiates Coverage On
12/04/2018 Broker: Needham Rating: Buy New Target: $27.0000
13/04/2018 Broker: SunTrust Rating: Buy New Target: $22.0000 Maintain
11/04/2018 Broker: Canaccord Genuity Rating: Buy New Target: $28.0000 Maintain
28/03/2018 Broker: JMP Securities Rating: Buy New Target: $42.0000
06/03/2018 Broker: Canaccord Genuity Rating: Buy New Target: $28.0 Maintain
13/02/2018 Broker: BTIG Research Rating: Buy New Target: $33 Initiates Coverage On
26/01/2018 Broker: Oppenheimer Old Rating: Outperform New Rating: Outperform Old Target: $24 New Target: $30 Maintain
04/01/2018 Broker: SunTrust Rating: Buy New Target: $24 Initiates Coverage On

Davenport & Company Llc decreased C (C) stake by 0.32% reported in 2018Q1 SEC filing. Davenport & Company Llc sold 6,805 shares as C (C)’s stock declined 11.86%. The Davenport & Company Llc holds 2.12M shares with $143.40 billion value, down from 2.13 million last quarter. C now has $171.59 billion valuation. The stock decreased 0.47% or $0.32 during the last trading session, reaching $67.29. About 17.53 million shares traded or 1.91% up from the average. Citigroup Inc. (NYSE:C) has risen 10.48% since June 14, 2017 and is uptrending. It has underperformed by 2.09% the S&P500. Some Historical C News: ; 09/04/2018 – Citigroup ‘Re-attributes’ Certain Costs Between Corporate/Other and Global Consumer Banking and Institutional Clients Group; 14/05/2018 – APPLIED MATERIALS INC AMAT.O : CITIGROUP RAISES TARGET PRICE TO $78 FROM $70; 03/05/2018 – WAYFAIR INC W.N : CITIGROUP RAISES TARGET PRICE TO $82 FROM $78; 24/04/2018 – MEDIA-Citigroup reorganizes credit markets unit – Bloomberg; 12/04/2018 – PFIZER: CITI SEES PFE INCREASING SHARE REPURCHASE PROGRAM TO OFFSET EPS DILUTION FROM HIGHER ANTICIPATED R&D INVESTMENT TO MONETISE CURRENT PIPELINE; 13/03/2018 – MARATHON PETROLEUM CORP MPC.N : CITIGROUP RAISES TARGET PRICE TO $80 FROM $75; 13/04/2018 – CITIGROUP INC – QTRLY ICG REVENUES OF $9.8 BLN INCREASED 6%; 21/03/2018 – Cash Cow: Morgan Stanley, Citi plan Brexit job moves – sources| Reuters; 29/03/2018 – Yahoo! UK: AMC is working with Citi on potential $2 bln float of Odeon cinemas; 18/04/2018 – Trade war would be ‘end of global recovery,’ says Citigroup economist

Among 41 analysts covering Citigroup Inc. (NYSE:C), 24 have Buy rating, 2 Sell and 15 Hold. Therefore 59% are positive. Citigroup Inc. has $215 highest and $4.0 lowest target. $73.37’s average target is 9.04% above currents $67.29 stock price. Citigroup Inc. had 126 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of Citigroup Inc. (NYSE:C) has “Buy” rating given on Thursday, June 22 by RBC Capital Markets. Oppenheimer maintained the stock with “Outperform” rating in Friday, October 16 report. As per Monday, July 31, the company rating was downgraded by BMO Capital Markets. Keefe Bruyette & Woods downgraded Citigroup Inc. (NYSE:C) on Tuesday, January 16 to “Hold” rating. Macquarie Research downgraded the shares of C in report on Friday, November 18 to “Neutral” rating. Buckingham Research maintained the shares of C in report on Friday, October 13 with “Buy” rating. HSBC upgraded the stock to “Buy” rating in Wednesday, April 11 report. The firm has “Buy” rating given on Monday, October 2 by Wells Fargo. RBC Capital Markets maintained Citigroup Inc. (NYSE:C) on Tuesday, January 19 with “Outperform” rating. The firm earned “Buy” rating on Tuesday, October 3 by Keefe Bruyette & Woods.

Davenport & Company Llc increased Nov (NYSE:NOV) stake by 1,215 shares to 12,164 valued at $447.76 million in 2018Q1. It also upped Qcom (NASDAQ:QCOM) stake by 55,036 shares and now owns 71,947 shares. Npv (NPV) was raised too.

More notable recent Citigroup Inc. (NYSE:C) news were published by: Seekingalpha.com which released: “Citigroup Inc. (C) Management presents at Morgan Stanley Financials Conference (Transcript)” on June 13, 2018, also Benzinga.com with their article: “Ahead Of Fed, AT&T-Time Warner Ruling Injects Some Optimism Into Market” published on June 13, 2018, Seekingalpha.com published: “Citigroup Will Thrive Regardless Of Interest Rates” on June 08, 2018. More interesting news about Citigroup Inc. (NYSE:C) were released by: Seekingalpha.com and their article: “Citi warns on bank job automation” published on June 12, 2018 as well as Bizjournals.com‘s news article titled: “Banking Roundup: Starbucks launches JPMorgan Visa cards… BofA’s virtual assistant Erica hits milestone” with publication date: June 13, 2018.

Investors sentiment decreased to 0.89 in Q1 2018. Its down 0.18, from 1.07 in 2017Q4. It dropped, as 89 investors sold C shares while 499 reduced holdings. 114 funds opened positions while 412 raised stakes. 1.90 billion shares or 4.45% less from 1.99 billion shares in 2017Q4 were reported. Lincluden reported 105,339 shares stake. Valley National Advisers Inc has invested 0.03% in Citigroup Inc. (NYSE:C). Argentiere Ag holds 29,800 shares or 0.86% of its portfolio. Chilton Mgmt Lc stated it has 1.06% in Citigroup Inc. (NYSE:C). Neuberger Berman Group Limited invested in 3.19 million shares. Strategic Wealth Group Ltd Llc owns 14,311 shares. Cibc Asset Mngmt Incorporated holds 0.15% or 335,064 shares in its portfolio. Van Hulzen Asset Ltd Limited Liability Company accumulated 60,230 shares or 1.25% of the stock. Bartlett And Limited Liability invested in 337 shares or 0% of the stock. First Dallas Secs holds 0.5% or 11,319 shares. Moreover, Pr Herzig Inc has 2.76% invested in Citigroup Inc. (NYSE:C) for 20,325 shares. Invsts Asset Mgmt Of Georgia Ga Adv holds 6,225 shares or 0.31% of its portfolio. Ancora Advisors has invested 0.08% in Citigroup Inc. (NYSE:C). Pennsylvania-based Pitcairn Company has invested 0.2% in Citigroup Inc. (NYSE:C). U S Glob holds 0.21% in Citigroup Inc. (NYSE:C) or 5,000 shares.

Analysts await Citigroup Inc. (NYSE:C) to report earnings on July, 13. They expect $1.56 EPS, up 22.83% or $0.29 from last year’s $1.27 per share. C’s profit will be $3.98 billion for 10.78 P/E if the $1.56 EPS becomes a reality. After $1.68 actual EPS reported by Citigroup Inc. for the previous quarter, Wall Street now forecasts -7.14% negative EPS growth.

Since February 27, 2018, it had 0 insider buys, and 7 sales for $5.91 million activity. $611,804 worth of Citigroup Inc. (NYSE:C) shares were sold by Hu W. Bradford. Another trade for 6,466 shares valued at $500,666 was made by Forese James A. on Tuesday, February 27. 7,000 shares were sold by Gerspach John C, worth $542,920 on Tuesday, February 27. $263,126 worth of Citigroup Inc. (NYSE:C) was sold by MURRAY JOSEPH MICHAEL on Tuesday, February 27. Callahan Don also sold $536,410 worth of Citigroup Inc. (NYSE:C) shares. On Tuesday, February 27 the insider Fraser Jane Nind sold $2.51 million.

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat genetic and infectious diseases in the United Kingdom and North America. The company has market cap of $211.49 million. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy and the infectious disease Clostridium difficile infection (CDI). It currently has negative earnings. The companyÂ’s lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial in patients with DMD; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials for the treatment of CDI disease.

More notable recent Summit Therapeutics plc (NASDAQ:SMMT) news were published by: Globenewswire.com which released: “Summit Therapeutics plc : Result of AGM” on June 07, 2018, also Globenewswire.com with their article: “Summit Therapeutics plc : 1st Quarter Results” published on June 05, 2018, Nasdaq.com published: “Summit Unveils Second Novel Target for Gonorrhoea at ASM Microbe 2018” on June 11, 2018. More interesting news about Summit Therapeutics plc (NASDAQ:SMMT) were released by: Nasdaq.com and their article: “Consolidated Research: 2018 Summary Expectations for Summit Therapeutics, Orbotech, Amphastar Pharmaceuticals …” published on June 05, 2018 as well as Globenewswire.com‘s news article titled: “Summit Therapeutics Unveils Second Novel Target for Gonorrhoea at ASM Microbe 2018” with publication date: June 11, 2018.

Citigroup Inc. (NYSE:C) Institutional Positions Chart